They showed that the results from this non-invasive EGFR mutation analysis were encouraging, and this combined workflow could represent a valuable means for informing therapy selection and for monitoring treatment of patients with NSCLC [75]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.